If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 41 - 50 of 268
Phase I Study of Iadademstat with Hypomethylating Agent in Patients with Myelodysplastic Syndrome
Objective
Phase I Study of Iadademstat with Azacitidine in Patients with Myelodysplastic Syndrome
Protocol No
IIT-GURU-IADADEMSTAT-MDS
Categories
Enhancing Reading Recovery in Aphasia With tDCS and PMT
Objective
Enhancing Reading Recovery in Aphasia With tDCS and PMT
Protocol No
NEURO-IIT-PSB-RAT
Categories
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Objective
Trial of neoadjuvant immunotherapy vs. SOC for resectable cutaneous squamous cell carcinoma
Protocol No
NRG-HN014
Categories
Early versus Late Endoscopic Temporary Stenting for Management of Refractory Benign Esophageal Strictures
Objective
Early vs Late Endoscopic Stenting for RBES
Protocol No
GI-IIT-DUA-RBES
Categories
RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Objective
RECOVER-SLEEP: Platform Protocol
Protocol No
PULM-DUKE-RECOVER-SLEEP
Categories
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Objective
ABP692 v Ocrelizumab in Relapsing-Remitting MS
Protocol No
NEURO-AMGEN-20230309
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Objective
Testing the combination of one approved drug and two experimental drugs in patients with relapsed or refractory multiple myeloma
Protocol No
ALLIANCE-A062101
Categories
An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Protocol No
LOXO-J5M-OX-JOXA
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
Objective
Long-term Extension Study of ABC008 in Subjects with Inclusion Body Myositis
Protocol No
NEURO-ABCURO-ABC008-IBM-202
WATCHMAN FLX Pro Left Atrial Appendage Closure Device With Alternative Post-Implant Monotherapy
Objective
SIMPLAAFY Clinical Trial
Protocol No
CVC-BOSTONSCI-SIMPLAAFY
Categories